Permanent birth
control in clinical trial
The lack of innovation for permanent birth control over the last half century leaves women struggling for viable options.
Birth Control
The only permanent birth control option available to women around the world is surgical tubal ligation, which was first performed in the 1880s. Although effective, surgery is associated with scarring from incisions, increased safety risks, recovery time and may not be a suitable option. The demand for accessible contraceptive options, particularly permanent, continues to rise.
- Daniels K. NCHS Data Brief, no 388. 2020
- Frattarelli 2007
Our Permanent Birth Control Solution
FemBloc features our proprietary delivery platform, which places balloon technology close to the opening of both fallopian tubes. This in-office approach is designed to eliminate the risks of incisions, anesthesia, and hormones. As a nonsurgical procedure that is implant free, FemBloc delivers a biopolymer that is expected to expel within 3 months leaving behind the woman’s own tissue in-growth to block the fallopian tubes. Confirmation of procedure success can be achieved after 90 days, which would provide women with a certainty no other option can achieve.
FemBloc is under clinical investigation in the U.S. (NCT05977751).
Clinical Trial Status
Biopolymer delivered
- Device placed through cervix into uterine cavity
- Balloon catheters are advanced and inflated
- Biopolymer is delivered into each fallopian tube
Biopolymer solidifies
- Device is removed after biopolymer delivery
- Biopolymer solidifies with contact to local tissue
Biopolymer degrades
- Biopolymer is designed to degrade over time and completely expel naturally
Confirmation of success
- Small section of each fallopian tube is closed with tissue ingrowth
- Ultrasound test confirms blocked tubes for permanent birth control
